^
+ Follow OVARIAN Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1292902
                    [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer
                    [Summary] => 

Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.

[DatePublished] => 2014-02-21 07:00:05 [ColumnID] => 0 [Focus] => 0 [AuthorID] => 1788586 [AuthorName] => Vonda J. Sines [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg ) [1] => Array ( [ArticleID] => 850063 [Title] => Women urged to start pelvic exams at 40 [Summary] =>

Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.

[DatePublished] => 2012-09-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 743585 [Title] => Roche launches drug for advanced ovarian cancer [Summary] =>

Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.

[DatePublished] => 2011-11-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 742896 [Title] => First-line treatment for advanced ovarian cancer [Summary] =>

Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.

[DatePublished] => 2011-11-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 701306 [Title] => Researchers analyze gene changes in ovarian cancer [Summary] =>

Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.

[DatePublished] => 2011-07-01 02:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => [SectionUrl] => [URL] => ) [6] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>

Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 685871 [Title] => CA 125 plus ultrasound detects early ovarian ca [Summary] =>

Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.

[DatePublished] => 2011-05-15 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [8] => Array ( [ArticleID] => 676897 [Title] => IVF regimen linked to ovarian cancer risk [Summary] =>

Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.

[DatePublished] => 2011-04-17 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>

Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
OVARIAN
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1292902
                    [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer
                    [Summary] => 

Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.

[DatePublished] => 2014-02-21 07:00:05 [ColumnID] => 0 [Focus] => 0 [AuthorID] => 1788586 [AuthorName] => Vonda J. Sines [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg ) [1] => Array ( [ArticleID] => 850063 [Title] => Women urged to start pelvic exams at 40 [Summary] =>

Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.

[DatePublished] => 2012-09-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 743585 [Title] => Roche launches drug for advanced ovarian cancer [Summary] =>

Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.

[DatePublished] => 2011-11-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 742896 [Title] => First-line treatment for advanced ovarian cancer [Summary] =>

Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.

[DatePublished] => 2011-11-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 701306 [Title] => Researchers analyze gene changes in ovarian cancer [Summary] =>

Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.

[DatePublished] => 2011-07-01 02:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => [SectionUrl] => [URL] => ) [6] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>

Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 685871 [Title] => CA 125 plus ultrasound detects early ovarian ca [Summary] =>

Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.

[DatePublished] => 2011-05-15 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [8] => Array ( [ArticleID] => 676897 [Title] => IVF regimen linked to ovarian cancer risk [Summary] =>

Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.

[DatePublished] => 2011-04-17 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>

Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with